Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy
- PMID: 30261097
- DOI: 10.1002/jso.25241
Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy
Abstract
Purpose: Genomic profiling for personalized targeted therapy has become standard of care. We report the success of genomic profiling of non-small cell lung cancer (NSCLC) obtained by trans-thoracic needle biopsy (TTNB) in a single center experience.
Materials and methods: Patients with NSCLC who underwent TTNB for genomic were identified. Pathology specimens were evaluated for tumor adequacy and then analyzed for selected exons of epidermal growth factor receptor, KRAS, BRAF, PIK3CA, and ERBB2. ALK rearrangements were detected with fluorescence in situ hybridization and/or immunohistochemistry. Technical success was recorded and the factors affecting successful profiling were evaluated. Complications (pneumothorax, hemorrhage, and admission) were recorded. Comparison of yield and complications were done between the two groups (core biopsy and fine needle aspiration only group). Utility of PET-CT to guide the needle track for optimized yield was assessed in a subset of patients.
Results: Between December 6, 2009, and December 30, 2016, 765 patients with NSCLC underwent TTNB. Five-hundred and seventy-seven of 765 (75%) of all TTNB were profiled, for genomic analysis. Five-hundred and eight of 577 (88%) were successfully profiled. The number of samples obtained ranged from 1 to 10 (1 to 2 cm, 18 to 20 G). Lesions biopsied ranged in size from 0.6 to 16 cm. No statistically significant difference was observed in the incidence of pneumothorax between two groups (P = 0.26). PET guidance was not found to be statistically significant ( P = 0.79) in the overall yield.
Conclusion: Computed tomographic guided TTNB is a safe and efficacious technique for genomic profiling, enables the acquisition of sufficient tissue for genetic mutation analyses allowing for personalized therapy with an acceptable complication rate.
Keywords: genomic profiling; lung cancer; mutation analysis; trans-thoracic needle biopsy; transthoracic needle biopsy.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.Korean J Radiol. 2021 Dec;22(12):2082-2093. doi: 10.3348/kjr.2021.0244. Epub 2021 Aug 31. Korean J Radiol. 2021. PMID: 34564960 Free PMC article.
-
Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.Lung Cancer. 2013 Oct;82(1):69-75. doi: 10.1016/j.lungcan.2013.07.010. Epub 2013 Aug 5. Lung Cancer. 2013. PMID: 23927885
-
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15. Lancet. 2016. PMID: 26777916
-
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.Mol Med Rep. 2018 Aug;18(2):2191-2197. doi: 10.3892/mmr.2018.9210. Epub 2018 Jun 22. Mol Med Rep. 2018. PMID: 29956783 Free PMC article.
-
Pneumothorax after transthoracic needle biopsy of lung lesions under CT guidance.J Thorac Dis. 2014 Mar;6 Suppl 1(Suppl 1):S99-S107. doi: 10.3978/j.issn.2072-1439.2013.12.08. J Thorac Dis. 2014. PMID: 24672704 Free PMC article. Review.
Cited by
-
Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.Korean J Radiol. 2021 Dec;22(12):2082-2093. doi: 10.3348/kjr.2021.0244. Epub 2021 Aug 31. Korean J Radiol. 2021. PMID: 34564960 Free PMC article.
-
[Progress in Image-planned and Real-time Image-guided Lung Cancer Biopsy in the Detection of Biomarkers].Zhongguo Fei Ai Za Zhi. 2023 Aug 20;26(8):630-638. doi: 10.3779/j.issn.1009-3419.2023.106.15. Zhongguo Fei Ai Za Zhi. 2023. PMID: 37752543 Free PMC article. Review. Chinese.
-
Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine.Curr Oncol Rep. 2022 Aug;24(8):1035-1044. doi: 10.1007/s11912-022-01271-7. Epub 2022 Apr 1. Curr Oncol Rep. 2022. PMID: 35362826 Review.
-
Risk factors for pulmonary infection in patients with non-small cell lung cancer: a Meta-analysis.BMC Pulm Med. 2024 Jul 22;24(1):353. doi: 10.1186/s12890-024-03171-x. BMC Pulm Med. 2024. PMID: 39039519 Free PMC article.
-
The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma.Pulm Med. 2020 Dec 23;2020:3578748. doi: 10.1155/2020/3578748. eCollection 2020. Pulm Med. 2020. PMID: 33425389 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous